Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Looking into Sagimet's potential drug candidate denifanstat for the treatment of Nonalcoholic steatohepatitis (NASH)

Ticker(s): SGMT

Who's the expert?

Institution: PIH Health Downey Hospital

A gastroenterologist in Downey, California and is affiliated with Kaiser Permanente Fontana and Ontario Medical Centers. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice between 11-20 years.
Currently manages 350 NASH patients
Very familiar with efruxifermin and its HARMONY Phase IIb trial

Interview Goal

to discuss the standard of care and the potential of Denifanstat, an investigational fatty acid synthase (FASN) inhibitor being developed by Sagimet Biosciences for the treatment of NASH.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.